There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioCardia (BCDA – Research Report) and Femasys (FEMY – Research Report) with bullish sentiments.
BioCardia (BCDA)
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on BioCardia, with a price target of $4.00. The company’s shares closed last Tuesday at $1.16.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of
BioCardia has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
See the top stocks recommended by analysts >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BCDA:
- BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
- BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results
- BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023
- BioCardia files $50M mixed securities shelf
- BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II
